{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:33:36Z","timestamp":1779114816698,"version":"3.51.4"},"reference-count":60,"publisher":"American Society for Microbiology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>A 3-dose (0, 1, and 6 months) intramuscular (3-IM) priming series of a human dose (HuAVA) and dilutions of up to 1:10 of anthrax vaccine adsorbed (AVA) provided statistically significant levels of protection (60 to 100%) against inhalation anthrax for up to 4 years in rhesus macaques. Serum anti-protective antigen (anti-PA) IgG and lethal toxin neutralization activity (TNA) were detectable following a single injection of HuAVA or 1:5 AVA or following two injections of diluted vaccine (1:10, 1:20, or 1:40 AVA). Anti-PA and TNA were highly correlated (overall<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>= 0.89 for log<jats:sub>10<\/jats:sub>-transformed data). Peak responses were seen at 6.5 months. In general, with the exception of animals receiving 1:40 AVA, serum anti-PA and TNA responses remained significantly above control levels at 28.5 months (the last time point measured for 1:20 AVA), and through 50.5 months for the HuAVA and 1:5 and 1:10 AVA groups (<jats:italic>P<\/jats:italic>&lt; 0.05). PA-specific gamma interferon (IFN-\u03b3) and interleukin-4 (IL-4) CD4<jats:sup>+<\/jats:sup>cell frequencies and T cell stimulation indices were sustained through 50.5 months (the last time point measured). PA-specific memory B cell frequencies were highly variable but, in general, were detectable in peripheral blood mononuclear cells (PBMC) by 2 months, were significantly above control levels by 7 months, and remained detectable in the HuAVA and 1:5 and 1:20 AVA groups through 42 months (the last time point measured). HuAVA and diluted AVA elicited a combined Th1\/Th2 response and robust immunological priming, with sustained production of high-avidity PA-specific functional antibody, long-term immune cell competence, and immunological memory (30 months for 1:20 AVA and 52 months for 1:10 AVA). Vaccinated animals surviving inhalation anthrax developed high-magnitude anamnestic anti-PA IgG and TNA responses.<\/jats:p>","DOI":"10.1128\/cvi.00324-12","type":"journal-article","created":{"date-parts":[[2012,8,30]],"date-time":"2012-08-30T05:58:59Z","timestamp":1346306339000},"page":"1730-1745","source":"Crossref","is-referenced-by-count":54,"title":["A Three-Dose Intramuscular Injection Schedule of Anthrax Vaccine Adsorbed Generates Sustained Humoral and Cellular Immune Responses to Protective Antigen and Provides Long-Term Protection against Inhalation Anthrax in Rhesus Macaques"],"prefix":"10.1128","volume":"19","author":[{"given":"Conrad P.","family":"Quinn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol L.","family":"Sabourin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"Niemuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera A.","family":"Semenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Rudge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J.","family":"Mayfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarad","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Mittler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris C.","family":"Ibegbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Wrammert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafi","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April M.","family":"Brys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denyse","family":"Levesque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Estep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy E.","family":"Barnewall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Plikaytis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Marano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2012,8,29]]},"reference":[{"key":"key20180919073629_B1","doi-asserted-by":"crossref","first-page":"25077","DOI":"10.1074\/jbc.M109.022061","article-title":"Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies","volume":"284","author":"Abboud","year":"2009","journal-title":"J. Biol. Chem."},{"key":"key20180919073629_B2","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1016\/S0264-410X(01)00197-9","article-title":"Passive transfer of protection against Bacillus anthracis infection in a murine model","volume":"19","author":"Beedham","year":"2001","journal-title":"Vaccine"},{"key":"key20180919073629_B3","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1021\/jm901024b","article-title":"Current and future medical approaches to combat the anthrax threat","volume":"53","author":"Bouzianas","year":"2010","journal-title":"J. Med. Chem."},{"key":"key20180919073629_B4","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1128\/IAI.00346-09","article-title":"Kinetics of lethal factor and poly-d-glutamic acid antigenemia during inhalation anthrax in rhesus macaques","volume":"77","author":"Boyer","year":"2009","journal-title":"Infect. Immun."},{"key":"key20180919073629_B5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/500148","article-title":"Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen","volume":"193","author":"Chen","year":"2006","journal-title":"J. Infect. Dis."},{"key":"key20180919073629_B6","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1128\/IAI.67.6.2957-2963.1999","article-title":"Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors","volume":"67","author":"Cirino","year":"1999","journal-title":"Infect. Immun."},{"key":"key20180919073629_B7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jim.2003.12.015","article-title":"Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system","volume":"286","author":"Crotty","year":"2004","journal-title":"J. Immunol. Methods"},{"key":"key20180919073629_B8","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.171.10.4969","article-title":"Cutting edge: long-term B cell memory in humans after smallpox vaccination","volume":"171","author":"Crotty","year":"2003","journal-title":"J. Immunol."},{"key":"key20180919073629_B9","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1016\/S0264-410X(01)00021-4","article-title":"Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin","volume":"19","author":"Fellows","year":"2001","journal-title":"Vaccine"},{"key":"key20180919073629_B10","first-page":"691","article-title":"Pathology of experimental inhalation anthrax in the rhesus monkey","volume":"73","author":"Fritz","year":"1995","journal-title":"Lab. Invest."},{"key":"key20180919073629_B11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1574-695X.2006.00114.x","article-title":"Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen","volume":"47","author":"Gubbins","year":"2006","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"key20180919073629_B12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/CVI.13.2.208-213.2006","article-title":"Neutralizing antibodies and persistence of immunity following anthrax vaccination","volume":"13","author":"Hanson","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073629_B13","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1016\/j.vaccine.2008.05.068","article-title":"An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals","volume":"26","author":"Hewetson","year":"2008","journal-title":"Vaccine"},{"key":"key20180919073629_B14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/1047322X.1990.10389587","article-title":"Estimation of average concentration in the presence of nondetectable values","volume":"5","author":"Hornung","year":"1990","journal-title":"Appl. Occup. Environ. Hyg."},{"key":"key20180919073629_B15","volume-title":"An assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program","author":"Joellenbeck","year":"2003"},{"key":"key20180919073629_B16","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1128\/IAI.00117-09","article-title":"Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen","volume":"77","author":"Kelly-Cirino","year":"2009","journal-title":"Infect. Immun."},{"key":"key20180919073629_B17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/IAI.70.2.544-550.2002","article-title":"Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization","volume":"70","author":"Kobiler","year":"2002","journal-title":"Infect. Immun."},{"key":"key20180919073629_B18","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1128\/IAI.00324-08","article-title":"The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-specific CD4+ T cells with a phenotype distinct from that of na\u00efve PA T cells","volume":"76","author":"Kwok","year":"2008","journal-title":"Infect. Immun."},{"key":"key20180919073629_B19","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1128\/IAI.01814-06","article-title":"Antigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine","volume":"75","author":"Laughlin","year":"2007","journal-title":"Infect. Immun."},{"key":"key20180919073629_B20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"key20180919073629_B21","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1128\/IAI.65.12.5171-5175.1997","article-title":"Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs","volume":"65","author":"Little","year":"1997","journal-title":"Infect. Immun."},{"key":"key20180919073629_B22","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.vaccine.2005.12.028","article-title":"Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine","volume":"24","author":"Little","year":"2006","journal-title":"Vaccine"},{"key":"key20180919073629_B23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0006-291X(05)81097-6","article-title":"Location of receptor-binding region of protective antigen from Bacillus anthracis","volume":"180","author":"Little","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"key20180919073629_B24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1099\/13500872-142-3-707","article-title":"Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies","volume":"142","author":"Little","year":"1996","journal-title":"Microbiology"},{"key":"key20180919073629_B25","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2003.12.027","article-title":"Development of an in vitro-based potency assay for anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"key":"key20180919073629_B26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.biologicals.2004.02.001","article-title":"Evaluation of an anti-rPA IgG ELISA for measuring the antibody response in mice","volume":"32","author":"Little","year":"2004","journal-title":"Biologicals"},{"key":"key20180919073629_B27","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.vaccine.2009.10.111","article-title":"Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques","volume":"28","author":"Livingston","year":"2010","journal-title":"Vaccine"},{"key":"key20180919073629_B28","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/S0264-410X(02)00151-2","article-title":"Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants","volume":"20","author":"Longworth","year":"2002","journal-title":"Vaccine"},{"key":"key20180919073629_B29","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1128\/IAI.73.12.8362-8368.2005","article-title":"Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region","volume":"73","author":"Mabry","year":"2005","journal-title":"Infect. Immun."},{"key":"key20180919073629_B30","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"key":"key20180919073629_B31","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0264-410X(97)00268-5","article-title":"Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers","volume":"16","author":"McBride","year":"1998","journal-title":"Vaccine"},{"key":"key20180919073629_B32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jim.2003.08.003","article-title":"Detection of antigen-specific T cell interferon gamma expression by ELISPOT and cytokine flow cytometry assays in rhesus macaques","volume":"282","author":"Pahar","year":"2003","journal-title":"J. Immunol. Methods"},{"key":"key20180919073629_B33","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1073\/pnas.95.6.3071","article-title":"Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns","volume":"95","author":"Peterson","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"key20180919073629_B34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1128\/MMBR.68.4.617-629.2004","article-title":"Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines","volume":"68","author":"Phipps","year":"2004","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"key20180919073629_B35","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2672.1999.00897.x","article-title":"In vitro correlate of immunity in an animal model of inhalational anthrax","volume":"87","author":"Pitt","year":"1999","journal-title":"J. Appl. Microbiol."},{"key":"key20180919073629_B36","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"key":"key20180919073629_B37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","article-title":"Anthrax vaccine: short-term safety experience in humans","volume":"20","author":"Pittman","year":"2001","journal-title":"Vaccine"},{"key":"key20180919073629_B38","doi-asserted-by":"crossref","first-page":"14070","DOI":"10.1073\/pnas.1006473107","article-title":"Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex","volume":"107","author":"Radjainia","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"key20180919073629_B39","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1128\/IAI.01254-08","article-title":"Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed","volume":"77","author":"Reason","year":"2009","journal-title":"Infect. Immun."},{"key":"key20180919073629_B40","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","article-title":"Search for correlates of protective immunity conferred by anthrax vaccine","volume":"69","author":"Reuveny","year":"2001","journal-title":"Infect. Immun."},{"key":"key20180919073629_B41","doi-asserted-by":"crossref","first-page":"e6351","DOI":"10.1371\/journal.pone.0006351","article-title":"Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection","volume":"4","author":"Rosenfeld","year":"2009","journal-title":"PLoS One"},{"key":"key20180919073629_B42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-8518-2-5","article-title":"Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed","volume":"2","author":"Sawada-Hirai","year":"2004","journal-title":"J. Immune Based Ther. Vaccines"},{"key":"key20180919073629_B43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2567.2004.01767.x","article-title":"Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions","volume":"111","author":"Scinicariello","year":"2004","journal-title":"Immunology"},{"key":"key20180919073629_B44","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CDLI.11.5.919-923.2004","article-title":"Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum","volume":"11","author":"Semenova","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"key20180919073629_B45","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1128\/CDLI.6.6.953-958.1999","article-title":"Comparison and characterization of immunoglobulin G subclasses among primate species","volume":"6","author":"Shearer","year":"1999","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"key20180919073629_B46","doi-asserted-by":"crossref","first-page":"15493","DOI":"10.1016\/S0021-9258(18)98643-6","article-title":"The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity","volume":"266","author":"Singh","year":"1991","journal-title":"J. Biol. Chem."},{"key":"key20180919073629_B47","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1128\/IAI.00529-07","article-title":"In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity","volume":"75","author":"Staats","year":"2007","journal-title":"Infect. Immun."},{"key":"key20180919073629_B48","volume-title":"Vaccines for the 21st century: a tool for decision making","author":"Stratton","year":"2001"},{"key":"key20180919073629_B49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CVI.00321-07","article-title":"Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor","volume":"15","author":"Taft","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073629_B50","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/IAI.52.2.356-363.1986","article-title":"Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity","volume":"52","author":"Turnbull","year":"1986","journal-title":"Infect. Immun."},{"key":"key20180919073629_B51","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1016\/j.vaccine.2004.02.037","article-title":"Vaccine-induced protection against anthrax in cheetah (Acinonyx jubatus) and black rhinoceros (Diceros bicornis)","volume":"22","author":"Turnbull","year":"2004","journal-title":"Vaccine"},{"key":"key20180919073629_B52","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1354\/vp.44-5-716","article-title":"Pathology of inhalational anthrax infection in the African green monkey","volume":"44","author":"Twenhafel","year":"2007","journal-title":"Vet. Pathol."},{"key":"key20180919073629_B53","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/IAI.67.4.1860-1865.1999","article-title":"Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin","volume":"67","author":"Varughese","year":"1999","journal-title":"Infect. Immun."},{"key":"key20180919073629_B54","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/01.LAB.0000080599.43791.01","article-title":"Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis)","volume":"83","author":"Vasconcelos","year":"2003","journal-title":"Lab. Invest."},{"key":"key20180919073629_B55","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1099\/0022-1317-51-10-821","article-title":"In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody","volume":"51","author":"Welkos","year":"2002","journal-title":"J. Med. Microbiol."},{"key":"key20180919073629_B56","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/00221287-147-6-1677","article-title":"The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores","volume":"147","author":"Welkos","year":"2001","journal-title":"Microbiology"},{"key":"key20180919073629_B57","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1128\/IAI.73.9.5978-5987.2005","article-title":"Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax","volume":"73","author":"Williamson","year":"2005","journal-title":"Infect. Immun."},{"key":"key20180919073629_B58","first-page":"1","article-title":"Use of anthrax vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"59","author":"Wright","year":"2010","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"key20180919073629_B59","first-page":"982","article-title":"The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation","volume":"122","author":"Zaucha","year":"1998","journal-title":"Arch. Pathol. Lab. Med."},{"key":"key20180919073629_B60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/HAB-2003-12404","article-title":"Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model","volume":"12","author":"Zhao","year":"2003","journal-title":"Hum. Antibodies"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00324-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T22:09:31Z","timestamp":1643321371000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00324-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,29]]},"references-count":60,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,10,25]]},"published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1128\/CVI.00324-12"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00324-12","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,29]]}}}